Quantcast

STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations

August 26, 2009
    PARIS, August 26 /PRNewswire-FirstCall/ --
    - Net Profit Up 11%
    - Strong Research and Investment Effort
    - Positive net Financial Position
    - Annual Growth Guidance Maintained at 10%

The Board of Directors, meeting on 25 August 2009 under the chairmanship
of Albert Saporta approved the 2009 half year financial statements:

    In million Euros         H1 2008      08/07      H1 2009
                                    %CA   Var.%             %CA
    Sales                87.0      100.0  16     97.6      100.0

    Cost of goods sold  (19.9)     (22.8) 18    (22.5)     (23.1)
    SG&A                (35.1)     (40.3) 12    (37.8)     (38.8)
    R&D net             (13.7)     (15.7) 22    (17.7)     (18.1)

    EBIT                 18.4       21.1  19     19.6       20.1
    Net result, group    12.0       13.8  19     13.4       13.7
    share

    EBITDA               21.5       24.8  14     24.1       24.7
    Capital expenditure  (4.9)      (5.6)(21)    (9.4)      (9.6)
    Free cash flow       10.0       11.5  43     14.5       14.8
    Net financial debts  4.2         4.9 (54)    (1.3)      (1.4)
    Equity               75.4       86.6  29     92.9       95.2

    EPS, diluted         0.90 EUR         19     1.01 EUR
    Dividend rate          39%         -1580%      35%
    Dividend per share   0.35 EUR         -      0.35 EUR

    (continued)

    In million Euros             09/08   B 2009   09/08   OL1 2009
                                 Var.%              %      Var.%
    Sales                        12     185.0     100.0   8       187.7

    Cost of goods sold           13     (44.2)    (23.9)  11      (44.4)
    SG&A                          8     (77.7)    (42.0)   7      (78.0)
    R&D net                      29     (34.2)    (18.5)  14      (36.3)

    EBIT                          7      29.0      15.6    3       29.0
    Net result, group share      11      19.6      10.6    3       19.7

    EBITDA                       12      37.5      20.2   56          -
    Capital expenditure          93     (21.6)    (11.7) 130          -
    Free cash flow               45       4.9       2.6  (66)         -
    Net financial debts        (131)      9.5           (818)         -
    Equity                       23     109.0             17          -

    EPS, diluted                 11      1.47 EUR          3       1.48 EUR
    Dividend rate             -1017%       34%        8              34%
    Dividend per share           -       0.50 EUR         11       0.50 EUR

Sales growth and financial position

In spite of the unfavourable economic background, sales were maintained
at a high level (up 12% – 11% organic, excluding foreign exchange effect),
due to the continuing growth of sublingual treatments. The launch of
ORALAIR(R), which started at the end of 2008 in Germany, has confirmed its
commercial success.

Selling, general and administrative expenses posted a moderate 8%
increase, substantially offset by the growth in sales. The 29% increase in
net R&D costs highlighted the continued dynamic development of allergen
tablets. In this context, operating profit grew by 7% to EUR 19.6 million.
Due to good control of financial expenses, net profit increased by 11% to EUR
13.4 million
. Diluted earnings per share amounted to EUR 1.01.

EBITDA grew by 12% to EUR 24.1 million. Against a background of sustained
investments, free cash flow rose by 45% to a positive EUR 14.5 million,
particularly due to a reduction in working capital requirements. For the
first time in 10 years, the net financial position was a positive EUR 1.3
million
.

The half-year financial report can be downloaded from the corporate
website: http://www.stallergenes.com

Significant recent transactions and events

The mutual recognition procedure for Oralair(R) (grass pollen
desensitization tablet) started at an operational level in the second quarter
and should lead to registration in most European countries by the end of 2009.

The phase IIb/III clinical study on the dust mite desensitization tablet
for adult rhinitis proved positive and will support a European registration
process. This study is a world first in dust mite immunotherapy, both in
terms of its scale and the quality of its results.

Outlook for 2009

The 2009 sales growth guidance remains set at 10%. This level of growth
should ensure operating profit remains at a level equivalent to 2008, against
a background of increased R&D investments. Investments will remain at a high
level, without calling into question the target of maintaining operating
profitability above 15% and a positive free cash flow.

Lastly, the second half-year will be marked by a number of significant
announcements. Five major phase II/III clinical study results are expected,
of which three, if proving positive, will allow for registration into
Oralair(R) phase III in the US, 3rd year of Oralair(R) long-term study in
Europe and phase III Staloral(R) study on asthma in China.

ABOUT STALLERGENES

Stallergenes is a European biopharmaceutical company dedicated to
desensitization therapies for the prevention and treatment of allergy-related
respiratory diseases, e.g. rhinoconjunctivitis and allergic asthma. A pioneer
and leader in sublingual desensitization treatments, Stallergenes devotes 21%
(gross) of its sales to Research and Development and is actively involved in
the development of a new therapeutic class: sublingual desensitization
tablets.

In 2008, Stallergenes had sales of EUR 171 million and provided
desensitization treatments to more than 500,000 patients.

    Euronext Paris (Compartment B)
    Component of SBF 120
    ISIN code: FR0000065674
    Reuters code: GEN.PA
    Bloomberg code: GEN.FP

Additional financial information is available at:
http://www.stallergenes.com

SOURCE Stallergenes


Source: newswire



comments powered by Disqus